Bhatt Padmanabh P.'s Form 4 filing
Supernus Pharmaceuticals, Inc. (SUPN) · filed Mar 18, 2026
- Accession no.
- 0001539215-26-000008
- Filed
- Mar 18, 2026
- Trade date
- Mar 16-18, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 14 non-derivative transactions and 8 derivative transactions. Open-market sales total $5.39M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Bhatt Padmanabh P.CIK 0001539215 | Officer (Sr. VP of IP, CSO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 16, 2026 | Common Stock | MOption exerciseAcquired | +22,750 | $36.75 | +$836,062.5 | 39,794 | Direct | |
| Mar 16, 2026 | Common Stock | MOption exerciseAcquired | +4,250 | $29.61 | +$125,842.5 | 44,044 | Direct | |
| Mar 16, 2026 | Common Stock | MOption exerciseAcquired | +18,000 | $32.20 | +$579,600 | 62,044 | Direct | |
| Mar 16, 2026 | Common Stock | MOption exerciseAcquired | +5,000 | $27.94 | +$139,700 | 67,044 | Direct | |
| Mar 16, 2026 | Common Stock | SSaleDisposed | −34,114 | $50.18F2 | −$1,711,840.52 | 32,930 | Direct | |
| Mar 16, 2026 | Common Stock | SSaleDisposed | −15,886 | $50.49F3 | −$802,084.14 | 17,044 | Direct | |
| Mar 17, 2026 | Common Stock | MOption exerciseAcquired | +22,750 | $39.40 | +$896,350 | 39,794 | Direct | |
| Mar 17, 2026 | Common Stock | MOption exerciseAcquired | +12,250 | $36.75 | +$450,187.5 | 52,044 | Direct | |
| Mar 17, 2026 | Common Stock | MOption exerciseAcquired | +15,000 | $38.60 | +$579,000 | 67,044 | Direct | |
| Mar 17, 2026 | Common Stock | SSaleDisposed | −27,710 | $49.95F4 | −$1,384,114.5 | 39,334 | Direct | |
| Mar 17, 2026 | Common Stock | SSaleDisposed | −22,290 | $50.73F5 | −$1,130,771.7 | 17,044 | Direct | |
| Mar 18, 2026 | Common Stock | MOption exerciseAcquired | +7,250 | $39.40 | +$285,650 | 24,294 | Direct | |
| Mar 18, 2026 | Common Stock | SSaleDisposed | −6,838 | $49.55F6 | −$338,822.9 | 17,456 | Direct | |
| Mar 18, 2026 | Common Stock | SSaleDisposed | −412 | $50.48 | −$20,797.76 | 17,044 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 16, 2026 | Common Stock | MOption exerciseDisposed | −22,750 | $0.00 | $0 | 12,250 | Direct | |
| Mar 16, 2026 | Common Stock | MOption exerciseDisposed | −4,250 | $0.00 | $0 | 0 | Direct | |
| Mar 16, 2026 | Common Stock | MOption exerciseDisposed | −18,000 | $0.00 | $0 | 0 | Direct | |
| Mar 16, 2026 | Common Stock | MOption exerciseDisposed | −5,000 | $0.00 | $0 | 15,000 | Direct | |
| Mar 17, 2026 | Common Stock | MOption exerciseDisposed | −22,750 | $0.00 | $0 | 7,250 | Direct | |
| Mar 17, 2026 | Common Stock | MOption exerciseDisposed | −12,250 | $0.00 | $0 | 0 | Direct | |
| Mar 17, 2026 | Common Stock | MOption exerciseDisposed | −15,000 | $0.00 | $0 | 5,000 | Direct | |
| Mar 18, 2026 | Common Stock | MOption exerciseDisposed | −7,250 | $0.00 | $0 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.34 to $50.34. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
Referenced by the price of 1 transaction in Table I.
- F3
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.35 to $50.77. The Reporting Person undertakes to provide to Supernus, any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
Referenced by the price of 1 transaction in Table I.
- F4
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.40 to $50.39. The Reporting Person undertakes to provide to Supernus, any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
Referenced by the price of 1 transaction in Table I.
- F5
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.40 to $51.15. The Reporting Person undertakes to provide to Supernus, any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
Referenced by the price of 1 transaction in Table I.
- F6
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.40 to $49.99. The Reporting Person undertakes to provide to Supernus, any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
Referenced by the price of 1 transaction in Table I.